IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION
申请人:LEBAN Johann
公开号:US20120196861A1
公开(公告)日:2012-08-02
The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
本发明涉及通式(I)的化合物,以及其药用可接受的盐或溶剂,作为抗炎和免疫调节剂。
[EN] NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS SE LIANT AU FXR (NR1 H4) ET MODULANT SON ACTIVITÉ
申请人:PHENEX PHARMACEUTICALS AG
公开号:WO2011020615A1
公开(公告)日:2011-02-24
The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
[EN] COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉS UTILES DANS LA MODULATION DU RÉCEPTEUR FARNÉSOÏDE X ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
申请人:INORBIT THERAPEUTICS AB
公开号:WO2020033382A1
公开(公告)日:2020-02-13
Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
Die Erfindung betrifft die Verwendung des bekannten α-(4-Methyl-phenylsulfonyl)-2, 6-dichlor-benzaldoxims der Formel (I).
oder des Ammoniumsalzes als Fungizide.